Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy (SoluWest)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02220114 |
|
Recruitment Status :
Completed
First Posted : August 19, 2014
Last Update Posted : April 24, 2018
|
Sponsor:
Targeon SAS
Collaborators:
Institut National de la Santé Et de la Recherche Médicale, France
Hospices Civils de Lyon
National Research Agency, France
Information provided by (Responsible Party):
Targeon SAS
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The sponsor is developing a new paediatric formulation of vigabatrin to better adjust the dose to body weight and to limit waste of unused drug. The currently marketed vigabatrin (Sabril™) form only exists as 500 mg film coated tablets (for adults and children above 6 years) and 500 mg granules for oral solution sachets (for infants and children below 6 years). Sabril™ is not adapted for administration to infants when a fraction of the sachet is needed. Manual splitting of the sachet or lengthy and error-prone dilutions are often required.
This study is a descriptive, non-randomized, open label multi-centric acceptability study in infants and children affected with infantile spasms. The primary objective is to describe the adherence to the new formulation. Secondary objectives include:
- evaluation of the palatability and user-friendliness of the new treatment,
- evaluation of the pharmacokinetic parameters of the new formulation,
- PK parameters,
- evaluation of the tolerance,
- measurement of taurine plasma levels. This study will recruit up to 40 patients with infantile spasms and pharmacoresistant partial epilepsy aged 1 month to 6 years in 23 clinical sites in France.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Infantile Spasms | Drug: Vigabatrin: Vigabatrin new ST formulation then Sabril® | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 38 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy. Observational, Descriptive, Open-label, Multi-centric, Non-randomized Study |
| Study Start Date : | May 2014 |
| Actual Primary Completion Date : | December 2016 |
| Actual Study Completion Date : | December 2016 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
CDKL5 deficiency disorder
Autosomal dominant partial epilepsy with auditory features
Early infantile epileptic encephalopathy 1
Pyridoxal 5'-phosphate-dependent epilepsy
Drug Information available for:
Vigabatrin
| Arm | Intervention/treatment |
|---|---|
|
Vigabatrin: Vigabatrin new ST formulation then Sabril®
Sabril®: sachet for oral solution 500 mg, 50 to 100mg/Kg/day, twice a day, 14 days. Vigabatrin new ST formulation: Soluble tablets 100 or 500 mg, 50 to 100mg/Kg/day, twice a day, 12 weeks. |
Drug: Vigabatrin: Vigabatrin new ST formulation then Sabril®
Dose and treatment regimen should be maintained as in first treatment phase. - At V4/D98, patients who received Sabril® "granules for oral solution" (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision). |
Primary Outcome Measures :
- Individual adherence to the new Soluble Tablets (ST) formulation of Vigabatrin (VGB) using Medication Event Monitoring System (MEMS) [ Time Frame: from V1 (day 1) to V3 (day 84), continuous assessment. ]Adherence will be assessed by measurement of the dosing history of patients using an electronic Medication Event Monitoring System (MEMS).The date and time of each opening will be recorded
Secondary Outcome Measures :
- Adherence to the new ST formulation and to Sabril® granules for oral solution, by treatment unit accountability [ Time Frame: VGB-ST: V1 (day 1) to V3 (day 84). Sabril®:V3 (day 85) to V4 (day 98) ]Accountability of used and unused treatment units, retrieved by the patient at V3 and V4
- palatability of the new ST formulation and of Sabril® "granules for oral solution". [ Time Frame: during 7 consecutive days: from D90 to D96 under Sabril® and from D29 to D35 under the new ST formulation ]Palatability of the treatment will be evaluated using a two face visual hedonic scale filled in by the parents and/or by the child, if feasible, on a daily basis. Each "face" of the scale will be assigned a score (1 to 2), and the average score will be calculated for the group. Palatability will be considered good if the average score for the group is at least 1.5 (out of a maximum of 2; Motte et al. 2005).
- Ease of use of the new ST formulation and of Sabril® "granules for oral solution". [ Time Frame: during 7 consecutive days: from D90 to D96 under Sabril® and from D29 to D35 under the new ST formulation. ]Ease of use will be evaluated using diaries filled by the parents or care-givers during 7 consecutive days: . Time required for preparation of both new ST formulation and Sabril® administrations will be averaged and compared, together with the global use satisfaction.
- Safety and tolerance [ Time Frame: Results of electroretinogram: when available from D1 to D126; Blood assessment: at D1 & D84; Vital signs at D1, D28, D84, D98 & D126; Adverse events, serious adverse events: evaluated for the duration of study participation (at D1, D28, D84, D98 & D126) ]VGB safety profile is well known. The new ST formulation is expected to be bioequivalent to Sabril®, and since the new formulation does not contain excipients known to have a recognized action or effect at the dose used, the safety of the new formulation should be similar to that of Sabril®. Hence no other measures specific to the new ST formulation are included in the clinical acceptability study.
- pharmacokinetic parameters for the new ST formulation (1 sample). Pharmacokinetic parameters for the new ST formulation (population PK) : Area under the curve (AUC), Tmax, Cmax, T½, Ka, V/F, Cl/F [ Time Frame: PK D84: 1 sample before treatment. ]The objective is to better characterize the developmental PK of vigabatrin during childhood.
- Evaluation of the taurine plasma levels in children treated by vigabatrin. Taurine plasma concentration will be measured and a relationship between vigabatrin exposition and taurine plasma levels will be sought. [ Time Frame: 1 sample will be drawn at V3 (day 84): just before treatment when patient is fasting. ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 1 Month to 6 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with diagnosed infantile spasms (IS) or pharmacoresistant partial onset seizures (POS).
- Infants > 1 month and < 6 months; infants > 6 months and < 2 years; and children > 2 years and < 6 years.
- Patients under Sabril® or naive patients.
- Patients under a twice-a-day posology of Sabril® or patients for whom vigabatrin will be given twice daily.
Non inclusion Criteria:
- Use of more than 2 other antiepileptic drugs as concomitant treatment (including steroids). Ketogenic diet can be in addition to these 2 other antiepileptic drugs.
- Subjects receiving vigabatrin through a gastric tube.
- Weight < 1.750 Kgs.
- Any planned major surgery within the duration of the trial.
- Participation in any other clinical trial within 3 months prior to V1.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02220114
Locations
| France | |
| Service de neurologie pédiatrique - CHU | |
| Amiens, France, 80054 | |
| Service de neurologie pédiatrique - CHU | |
| Angers, France, 49033² | |
| Service de neuropédiatrie - CHU Pellegrin Enfants | |
| Bordeaux, France, 33076 | |
| Service de neurologie infantile - Hôpital Salengro | |
| Lille, France, 59037 | |
| Service de nuerologie pédiatrique - Hôpital Femme Mère Enfant | |
| Lyon, France, 69677 | |
| Service de neurologie pédiatrique - Hôpital de la Timone | |
| Marseille, France, 13385 | |
| Service de neurologie pédiatrique - Hôpital Necker Enfants Malades | |
| Paris, France, 75015 | |
| Service de neuropédiatrie - Hôpital Robert Debré | |
| Paris, France, 75019 | |
| Service de neurologie pédiatrique - Hôpital Sud | |
| Rennes, France, 35203 | |
| Centre référent des épilepsies rares pédiatrique associé - Hôpital de Hautepierre | |
| Strasbourg, France, 67098 | |
| Service de neuropédiatrie - Hôpital Purpan | |
| Toulouse, France, 331059 | |
| Service de neuropédiatrie - Hôpital de Clocheville | |
| Tours, France, 37044 | |
Sponsors and Collaborators
Targeon SAS
Institut National de la Santé Et de la Recherche Médicale, France
Hospices Civils de Lyon
National Research Agency, France
Investigators
| Principal Investigator: | Rima NABBOUT | Hôpital Necker Enfants Malades - APHP |
| Responsible Party: | Targeon SAS |
| ClinicalTrials.gov Identifier: | NCT02220114 History of Changes |
| Other Study ID Numbers: |
TGO-VGB-III-01 |
| First Posted: | August 19, 2014 Key Record Dates |
| Last Update Posted: | April 24, 2018 |
| Last Verified: | April 2018 |
Keywords provided by Targeon SAS:
|
Infantile spasms vigabatrin soluble tablets |
acceptability adherence pharmacokinetics |
Additional relevant MeSH terms:
|
Epilepsy Spasm Muscle Cramp Epilepsies, Partial Spasms, Infantile Brain Diseases Central Nervous System Diseases Nervous System Diseases Neuromuscular Manifestations Neurologic Manifestations Signs and Symptoms |
Muscular Diseases Musculoskeletal Diseases Epilepsy, Generalized Vigabatrin Anticonvulsants Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action GABA Agents Neurotransmitter Agents Physiological Effects of Drugs |